To get a drug approved by the Food and Drug Administration, it may take 15 years and $1 billion, but the process is well-defined. However, as of now, there is no such pathway for diagnostic tests.
Board of Directors
Joseph R. (Bob) Assenzo, PhD
Director of Education
Rachel Behrman, PhD
Liaison Member of the Board
Associate Commissioner for Clinical Programs and Director,
Office of Critical Path Programs
Food and Drug Administration (FDA)
J. Lyle Bootman, PhD, ScD
Dean, College of Pharmacy; Professor of Pharmacy, Medicine, and Public Health;
Executive Director, Center for Health Outcomes and PharmacoEconomic
(HOPE) Research
John L. Carter, MBA
Retired 1987: General Manager, IBM Tucson
Retired 1996: Executive Vice President and CFO
Peter B. Corr, PhD
General Partner
Celtic Therapeutics Management, L.L.L.P
M. Wainwright Fishburn, Jr.
Jeffrey E. Jacob, SM
CEO of Cancer Prevention Pharmaceuticals
LLC
President and CEO
Shaun A. Kirkpatrick, MA
President and CEO
Research Corporation Technologies, Inc.
The Honorable James T. Kolbe
Senior Transatlantic Fellow
German Marshall Fund of the United States
Walter H. Moos, PhD
Vice President, Biosciences Division
Leslie P. Tolbert, PhD
Vice President for Research, Graduate Studies, and Economic Development
Janet Woodcock, MD
Liaison Member of the Board
Director, Center for Drug Evaluation and Research (CDER)
Alastair J.J. Wood, MB, ChB
Managing Director
Raymond L. Woosley, MD, PhD
Chairman of the Board
President and CEO